Navigation Links
Einstein receives $4 million to test HPV microbicide
Date:7/23/2010

on health. "If the trial is successful, it will yield a product that empowers women to protect themselves, since they can personally control how it is used."

This study is built upon previous studies of Carraguard. While a recent phase 3 trial using the product did not demonstrate effectiveness against HIV, it was shown to be safe. Recent laboratory tests indicate that carrageenan, the active ingredient in Carraguard, is about 1000 times more effective against HPV than against HIV.

Dr. Einstein's study will be a combined clinical trial and translational research project. Two hundred women will be assigned to use either Carraguard or a placebo gel. At the end of one year, the participants will be examined to determine if Carraguard was protective against acquiring HPV infections. In addition, assays will be done in the lab to assess the compound's activity and to develop a predictive test for efficacy.

Dr. Einstein will be collaborating with other Einstein scientists on the research, including Betsy Herold, M.D., professor of pediatrics, of microbiology & immunology, and of obstetrics & gynecology and women's health. Laboratory tests used in this study were developed by Dr. Herold to evaluate HIV microbicides. Efforts by her lab will include taking samples to look for any sign that the gel alters the body's natural defenses against the virus. If so, that would point to potential problems with efficacy and safety in clinical use.

"This trial is really taking the microbicide field in an exciting new direction," said Dr. Herold. "The potential for an effective microbicide agent against HPV could have an enormous impact on public health in the U.S. and around the globe, especially in populations where infection rates are high."

Drs. Herold and Einstein have been working closely with Marla Keller, M.D., associate professor of medicine and of obstetrics & gynecology and women's health, another prominent investigator in this stu
'/>"/>

Contact: Deirdre Branley
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Einstein researcher awarded prestigious cancer research grant
2. Einstein-Montefiore research tackles childhood obesity in the Bronx
3. Einstein researchers discover 2 new ways to kill TB
4. Einstein receives high-risk/high-reward cancer research funding
5. Einstein to develop anti-HIV drug delivery system
6. Einstein scientists move closer to a safer anthrax vaccine
7. Einstein researchers devise a fast and sensitive way to detect ricin
8. NIH funds research center for womens reproductive health at Einstein
9. Einstein and Pitt researchers develop new TB test that will dramatically cut diagnosis time
10. Empire State Stem Cell Board awards $12.7 million to Albert Einstein College of Medicine
11. Einstein scientists receive $10 million NIH grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... inhibits RSV infection , Respiratory syncytial virus ... tract infections, generating life-threating illness in very young ... are limited. RSV enters host cells through the ... fusogenic bundle. Small interfering peptides that prevent bundle ... peptides are highly susceptible to degradation. In this ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
(Date:4/17/2014)... marrow need to produce hydrogen sulfide in order to ... new study from the Center for Craniofacial Molecular Biology ... , Professor Songtao Shi, principal investigator on the project, ... cells governs the flow of calcium ions. The essential ... in osteogenesis, or the creation of new bone tissue, ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... 16, 2011The American Association for the Advancement of ... Srivastava, MD, a Fellow for his efforts to ... directs cardiac and stem cell research at Gladstone, ... research efforts are focused in the areas of ...
... (OGI) has awarded two research facilities with $10,000 each ... the work of Ontario researchers., ,The two recipients ... The Hospital for Sick Children (SickKids) in Toronto and ... StemCore Laboratories based at the Ottawa Hospital Research Institute. ...
... animal, from a blue whale to a human being, ... the cells in its body will die without reproducing; ... the next generation. How could the extreme degree ... aren,t all creatures unicellular individualists determined to pass on ...
Cached Biology News:Gladstone scientist Deepak Srivastava named fellow of the AAAS 22 research facilities awarded technology seeding grants 2Close family ties keep microbial cheaters in check, study finds 2Close family ties keep microbial cheaters in check, study finds 3Close family ties keep microbial cheaters in check, study finds 4Close family ties keep microbial cheaters in check, study finds 5
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... BALTIMORE, March 24, 2011 Champions Biotechnology, Inc. ... a technology collaboration agreement with Cephalon, Inc. in ... on two proprietary chemical compounds, CEP-32496, an inhibitor ... ALK-FAK inhibitor, provided by Cephalon to determine the ...
... Calif., March 24, 2011 ValGenesis, Inc., an ... solutions, today announced the availability of its industry-proven ... (SaaS) offering hosted on MUSA,s Validated Cloud. ... Lifecycle Management solution accessible via the Internet through ...
... Rules-Based Medicine, Inc. (RBM), a leading provider of innovative ... OncologyMAP ® , a powerful tool developed at the ... Institute. Through quantitative measurement of 101 cancer-related proteins, OncologyMAP ... on biological pathways that could hold the key to ...
Cached Biology Technology:Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 3Announcing ValGenesis On-Demand SaaS Solution 2Announcing ValGenesis On-Demand SaaS Solution 3Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development 2
... protein assay kit I provides reagents and a ... presence of reducing agents and detergents. The RC ... kit includes reagents and standards sufficient for 500 ... ml RC reagent II, 250 ml alkaline copper ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... three-color reagent kit for determining the absolute ... blood samples, mobilized peripheral blood samples, and ... a total nucleated cell count and a ... is designed for use in the BD ...
... Rhodopsin is a glycoprotein which is ... and reptiles. The rhodopsin protein is present ... Immunogen: Membrane preparation from ... This antibody specifically labels the axons andsynaptic ...
Biology Products: